Small Molecules
7 March 2016
Oral OTEZLA® (Apremilast) Long-Term Safety Data Presented at American Academy of Dermatology Congress7 March 2016
Antibe Therapeutics’ ATB-346 Receives Approval for Phase 2 Clinical Trial in Osteoarthritis Patients7 March 2016
Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor7 March 2016
Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference5 March 2016
U.S. FDA Approves IMBRUVICA® (ibrutinib) for First-line Treatment of Chronic Lymphocytic LeukemiaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports